Short Interest in Tyra Biosciences, Inc. (NASDAQ:TYRA) Increases By 30.5%

Tyra Biosciences, Inc. (NASDAQ:TYRA) was the recipient of a significant increase in short interest in the month of February. As of February 15th, there was short interest totalling 3,680,000 shares, an increase of 30.5% from the January 31st total of 2,820,000 shares. Currently, 11.9% of the shares of the company are sold short. Based on an average trading volume of 234,600 shares, the days-to-cover ratio is currently 15.7 days.

Tyra Biosciences Trading Up 1.1 %

TYRA traded up $0.12 on Wednesday, reaching $11.07. The company had a trading volume of 192,909 shares, compared to its average volume of 262,582. The company has a market capitalization of $560.02 million, a P/E ratio of -6.83 and a beta of 1.05. The company has a fifty day moving average of $14.10 and a 200-day moving average of $17.70. Tyra Biosciences has a one year low of $10.65 and a one year high of $29.60.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on TYRA shares. HC Wainwright reaffirmed a “buy” rating and issued a $30.00 price objective on shares of Tyra Biosciences in a report on Tuesday, February 18th. UBS Group began coverage on shares of Tyra Biosciences in a research report on Tuesday, January 7th. They issued a “buy” rating and a $28.00 target price for the company. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Tyra Biosciences has an average rating of “Buy” and a consensus price target of $30.50.

Insider Buying and Selling

In other Tyra Biosciences news, Director Nina S. Kjellson sold 7,779 shares of the stock in a transaction on Thursday, January 16th. The stock was sold at an average price of $16.29, for a total value of $126,719.91. Following the sale, the director now directly owns 447,857 shares of the company’s stock, valued at $7,295,590.53. This trade represents a 1.71 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Insiders have sold a total of 21,998 shares of company stock worth $344,818 over the last quarter. 15.40% of the stock is owned by company insiders.

Institutional Trading of Tyra Biosciences

A number of institutional investors have recently made changes to their positions in TYRA. KLP Kapitalforvaltning AS bought a new stake in Tyra Biosciences during the fourth quarter worth approximately $31,000. US Bancorp DE acquired a new stake in shares of Tyra Biosciences in the fourth quarter valued at $50,000. BNP Paribas Financial Markets bought a new position in Tyra Biosciences during the fourth quarter valued at about $60,000. Aquatic Capital Management LLC acquired a new position in Tyra Biosciences during the fourth quarter worth about $64,000. Finally, Wells Fargo & Company MN grew its holdings in Tyra Biosciences by 51.7% during the fourth quarter. Wells Fargo & Company MN now owns 9,493 shares of the company’s stock worth $132,000 after acquiring an additional 3,236 shares during the period. 84.14% of the stock is owned by institutional investors and hedge funds.

Tyra Biosciences Company Profile

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.